William P. Donnelly Appointed to Quanterix’s Board of Directors
21 Agosto 2023 - 3:30PM
Business Wire
Quanterix Corporation (NASDAQ: QTRX), a company fueling
scientific discovery and breakthrough diagnostics through
ultrasensitive biomarker detection, today announced that it
appointed William (Bill) P. Donnelly to its Board of Directors.
Mr. Donnelly brings many years of senior leadership experience
in the life science tools industry, including 21 years at
Mettler-Toledo International Inc., where he was executive vice
president and chief financial officer. While at Mettler-Toledo, he
was responsible for finance, investor relations, supply chain, and
information technology. Over his tenure, he strategically oversaw
the company from a leveraged buy-out to an IPO and advised the
company once it successfully went public. He brings to Quanterix a
breadth of experience.
Mr. Donnelly received a Bachelor of Science in business
administration from John Carroll University, where he currently
serves as a chairman on the Board of Trustees. Mr. Donnelly also
serves as lead independent director and chair of the nominating and
corporate governance committee of Ingersoll Rand Inc.
“We’re excited about Bill joining us at a time when we’re
building the global infrastructure to support physician diagnosis
of Alzheimer’s disease. Quanterix is rapidly driving the next ten
years of blood biomarker advancement in neurology, and Bill’s
experience in pursuit of our mission will be valuable,” said Masoud
Toloue, CEO at Quanterix.
“I’m eager to leverage my experience to further Quanterix’s
business strategy and its next stage of growth,” said Donnelly.
“Quanterix is in the midst of an active transformation, in an
exciting market that is ripe for growth, continued discovery, and
innovation. I’m looking forward to joining the Quanterix team and
getting started as a director.”
To learn more about Quanterix’s Simoa® technology, visit:
https://www.quanterix.com/simoa-technology/.
About Quanterix
From discovery to diagnostics, Quanterix’s ultrasensitive
biomarker detection is fueling breakthroughs only made possible
through its unparalleled sensitivity and flexibility. The Company’s
Simoa® technology has delivered the gold standard for earlier
biomarker detection in blood, serum or plasma, with the ability to
quantify proteins that are far lower than the Limit of
Quantification (LoQ) of conventional analog methods. Its
industry-leading precision instruments, digital immunoassay
technology and CLIA-certified Accelerator laboratory have supported
research that advances disease understanding and management in
neurology, oncology, immunology, cardiology and infectious disease.
Quanterix has been a trusted partner of the scientific community
for nearly two decades, powering research published in more than
2,000 peer-reviewed journals. Find additional information about the
Billerica, Massachusetts-based company at https://www.quanterix.com
or follow us on Twitter and LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,”
“estimate,” “intend” and similar expressions (as well as other
words or expressions referencing future events, conditions or
circumstances) are intended to identify forward-looking statements.
Forward-looking statements in this news release are based on
Quanterix’s expectations and assumptions as of the date of this
press release. Each of these forward-looking statements involves
risks and uncertainties. Factors that may cause Quanterix’s actual
results to differ from those expressed or implied in the
forward-looking statements in this press release are discussed in
Quanterix’s filings with the U.S. Securities and Exchange
Commission, including the “Risk Factors” sections contained
therein. Except as required by law, Quanterix assumes no obligation
to update any forward-looking statements contained herein to
reflect any change in expectations, even as new information becomes
available.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230821910145/en/
Quanterix Media Contact: Maya Nimnicht, PAN Communications (510)
334-6273 pan.quanterix@pancomm.com
Investor Relations Contact: Ed Joyce, Quanterix (610) 306-9917
ejoyce@quanterix.com
Quanterix (NASDAQ:QTRX)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Quanterix (NASDAQ:QTRX)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024